pharma · Generalized Myasthenia Gravis · Chronic inflammatory demyelinating polyneuropathy (CIDP)
Argenx
argenx
argenx is a pharma organization headquartered in GENT, BE. Primary therapeutic focus areas include Generalized Myasthenia Gravis, Chronic inflammatory demyelinating polyneuropathy (CIDP), Bullous Pemphigoid, Thyroid Eye
33 Arch Street, Suite 3201, Boston, MA 02110, US HQ
2008 Founded
2,179 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 33 Arch Street, Suite 3201, Boston, MA 02110, US
- Founded
- 2008
- Employees
- 2,179
- Programs
- 32
- Drugs
- 16
- Patents
- 0
ARGX-117, ARGX-113
Phase 2 · small molecule · AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG
ARGX-117, ARGX-113 for AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG is a Phase 2 program (small_molecule) at argenx with 1 ClinicalTrials.gov record(s).
Internal code ARGX-999-2-MG-20001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- argenx
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG
- Status
- active
- Trials
- 1